Glytactin
Commercial- Indications
- Phenylketonuria (PKU)
Company intelligence / Profile preview
Ajinomoto Cambrooke has developed and commercialized a range of medical nutrition therapies—primarily protein and amino acid-based formulas—for rare metabolic disorders and intractable epilepsy. Their lead products are supported by clinical evidence for nutritional management. The company continues to innovate with new pipeline candidates targeting additional metabolic and renal conditions.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ajinomoto Cambrooke.